Harada H, Iizuka K, Kamijo T, Akahane K, Yamamoto R, Nakano Y, Tsubaki A, Kubota T, Shimaoka I, Umeyama H
Central Research Laboratories, Kissei Pharmaceutical Co., Ltd., Nagano, Japan.
Chem Pharm Bull (Tokyo). 1990 Nov;38(11):3042-7. doi: 10.1248/cpb.38.3042.
The experimental details for the synthesis of human renin inhibitors are described. In order to avoid metabolic degradation of the Phe-His (P3-P2) amide bond in transition-state analogs, structurally modified acyl residues (P4-P3) were incorporated into the inhibitors. Compound 1a, which contained 2-(1-naphthylmethyl)-3-(N-phenethylcarbamoyl)propionyl residue (P4-P3) with a retro-inverso amide bond, L-histidine, and norstatine isoamylamide residue (P1-P1) as a transition-state mimic, had potent human renin inhibitory activity, and it lowered blood pressure when administered orally to common marmosets.